Effects of a Isokinetic Exercise in Women With Fibromyalgia
Key facts
- Where
- Valladolid, SpainSee the site
Where in Spain
- Miguel de Cervantes European UniversityValladolid, SpainContact: Francisco Javier Gutiérrez Pecharromán, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- European University Miguel de Cervantes
- Trial code
- NCT07483216
- Record updated
- 16 April 2026
- Original description
Fibromyalgia is a chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and functional impairment, which significantly affects quality of life. Physical exercise is considered one of the most effective non-pharmacological interventions for the management of this condition; however, uncertainty remains regarding the most appropriate type, intensity, and frequency of exercise for different patient profiles. The aim of this study is to analyze the effects of a microdoses isokinetic exercise program on physical condition, perceived pain, inflammatory profile and quality of life in women diagnosed with fibromyalgia.Read full original descriptionShow less
Effects of a Microdoses Isokinetic Exercise Protocol in Women With Fibromyalgia
Fibromyalgia is a chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and functional impairment, which significantly affects quality of life. Physical exercise is considered one of the most effective non-pharmacological interventions for the management of this condition; however, uncertainty remains regarding the most appropriate type, intensity, and frequency of exercise for different patient profiles. The aim of this study is to analyze the effects of a microdoses isokinetic exercise program on physical condition, perceived pain, inflammatory profile and quality of life in women diagnosed with fibromyalgia.
Inclusion: Women aged ≥ 18 years diagnosed with fibromyalgia according to current clinical criteria; Clinical and pharmacological stability during the weeks prior to participation in the study; Ability to perform supervised exercise and to complete the assessments; Written informed consent.
Exclusion: Any condition that, in clinical judgement, prevents them from following the protocol safely; Cardiovascular, neurologic, musculoskeletal or systemic pathology that contraindicate the performance of exercise; Significant change in pharmacological treatment during the period immediately preceding the study.